Liquidia Technologies Inc (LQDA)vsZoetis Inc (ZTS)
LQDA
Liquidia Technologies Inc
$36.61
+4.01%
HEALTHCARE · Cap: $3.10B
ZTS
Zoetis Inc
$116.71
+0.67%
HEALTHCARE · Cap: $51.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 5880% more annual revenue ($9.47B vs $158.32M). ZTS leads profitability with a 28.2% profit margin vs -43.5%. ZTS earns a higher WallStSmart Score of 64/100 (C+).
LQDA
Hold38
out of 100
Grade: F
ZTS
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LQDA.
Margin of Safety
-29.1%
Fair Value
$99.69
Current Price
$116.71
$17.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 3055.0% year-over-year
Strong operational efficiency at 21.5%
Every $100 of equity generates 66 in profit
Strong operational efficiency at 34.7%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Areas to Watch
0.0% earnings growth
Trading at 71.8x book value
ROE of -111.1% — below average capital efficiency
Currently unprofitable
Expensive relative to growth rate
Trading at 14.9x book value
3.0% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : LQDA
The strongest argument for LQDA centers on Revenue Growth, Operating Margin. Revenue growth of 3055.0% demonstrates continued momentum.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.2% and operating margin at 34.7%.
Bear Case : LQDA
The primary concerns for LQDA are EPS Growth, Price/Book, Return on Equity.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.85 is elevated, increasing financial risk.
Key Dynamics to Monitor
LQDA profiles as a hypergrowth stock while ZTS is a value play — different risk/reward profiles.
ZTS carries more volatility with a beta of 0.95 — expect wider price swings.
LQDA is growing revenue faster at 3055.0% — sustainability is the question.
ZTS generates stronger free cash flow (732M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (64/100 vs 38/100), backed by strong 28.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Liquidia Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?